FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2332409793> ?p ?o ?g. }

• W2332409793 endingPage "367" @default.
• W2332409793 startingPage "367.2" @default.
• W2332409793 abstract "<h3>Background</h3> ACR/EULAR definitions of remission is recommended to assess clinical outcome to achieve treat to target for RA treatment (1). However, the role of new remission criteria is not still clear as for bio-free remission. <h3>Objectives</h3> In order to investigate how Boolean definition criteria for remission in infliximab treatment for rheumatoid arthritis (RA) relate clinical factors, we analyzed bio-free and drug-free remission rate by treatment of infliximab in 212 RA patients. <h3>Methods</h3> 212 patients treated with infliximab, 181 female, 31 male, mean age of 59.4 years old, mean disease duration of 13 years, mean MTX dosage of 6.1 mg/weeks and mean PSL dosage of 2.7 mg/day. Up to 3 years after discontinuation of infliximab, remission rate by DAS28 (CRP), SDAI and Boolean definition criteria was investigated. In clinical data, C-reactive protein (CRP), matrix metalloproteinase (MMP)-3, rheumatoid factor and CCP antibody levels were followed up regularly. <h3>Results</h3> 32 out of 212 patients (15%) showed bio-free remission including 4 male and 28 female, mean ages of 57.2 years, mean disease duration of 89 months. Less than 5 years of disease duration, bio-free rate was 23% and within 2 years of disease duration, it showed 25%. At 52 weeks, SDAI and Boolean remission criteria were 19% and 15%. All cases of Boolean remission criteria (15%) showed bio-free remission (15%) and correlated with each other significantly (p<0.001) after an average of 2.2 years of treatment of infliximab. On the other hand, drug-free remission was 11 patients (5.2%) with mean age of 55.7 years, mean disease duration of 57 months. An average of three yeas after drug-remission, 2 out of 11 flared and restarted MTX treatment. The related factors of flare-up cases were rheumatoid factor and disease duration. CCP antibody was not changed to normal level in positive cases after drug-free remission. <h3>Conclusions</h3> Boolean remission criteria by treatment of infliximab correlated with bio-free remission significantly. Therefore Boolean remission may be useful criteria to predict the bio-free remission in infliximab treatment for RA. <h3>References</h3> Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 63:573-86,2011. <h3>Disclosure of Interest</h3> None Declared" @default.
• W2332409793 created "2016-06-24" @default.
• W2332409793 creator A5008742394 @default.
• W2332409793 creator A5017784077 @default.
• W2332409793 creator A5028588267 @default.
• W2332409793 date "2013-06-01" @default.
• W2332409793 modified "2023-09-30" @default.
• W2332409793 title "FRI0165 Boolean definition criteria is useful to predict for bio-free remission in treatment with infliximab for rheumatoid arthritis" @default.
• W2332409793 doi "https://doi.org/10.1136/annrheumdis-2012-eular.2622" @default.
• W2332409793 hasPublicationYear "2013" @default.
• W2332409793 type Work @default.
• W2332409793 sameAs 2332409793 @default.
• W2332409793 citedByCount "0" @default.
• W2332409793 crossrefType "journal-article" @default.
• W2332409793 hasAuthorship W2332409793A5008742394 @default.
• W2332409793 hasAuthorship W2332409793A5017784077 @default.
• W2332409793 hasAuthorship W2332409793A5028588267 @default.
• W2332409793 hasConcept C126322002 @default.
• W2332409793 hasConcept C2777138892 @default.
• W2332409793 hasConcept C2777575956 @default.
• W2332409793 hasConcept C2778715236 @default.
• W2332409793 hasConcept C2779134260 @default.
• W2332409793 hasConcept C71924100 @default.
• W2332409793 hasConcept C90924648 @default.
• W2332409793 hasConceptScore W2332409793C126322002 @default.
• W2332409793 hasConceptScore W2332409793C2777138892 @default.
• W2332409793 hasConceptScore W2332409793C2777575956 @default.
• W2332409793 hasConceptScore W2332409793C2778715236 @default.
• W2332409793 hasConceptScore W2332409793C2779134260 @default.
• W2332409793 hasConceptScore W2332409793C71924100 @default.
• W2332409793 hasConceptScore W2332409793C90924648 @default.
• W2332409793 hasIssue "Suppl 3" @default.
• W2332409793 hasLocation W23324097931 @default.
• W2332409793 hasOpenAccess W2332409793 @default.
• W2332409793 hasPrimaryLocation W23324097931 @default.
• W2332409793 hasRelatedWork W2015993259 @default.
• W2332409793 hasRelatedWork W2026061363 @default.
• W2332409793 hasRelatedWork W2329642249 @default.
• W2332409793 hasRelatedWork W2341953096 @default.
• W2332409793 hasRelatedWork W2411569365 @default.
• W2332409793 hasRelatedWork W2755566013 @default.
• W2332409793 hasRelatedWork W2990434109 @default.
• W2332409793 hasRelatedWork W3000815262 @default.
• W2332409793 hasRelatedWork W4205530129 @default.
• W2332409793 hasRelatedWork W646013988 @default.
• W2332409793 hasVolume "71" @default.
• W2332409793 isParatext "false" @default.
• W2332409793 isRetracted "false" @default.
• W2332409793 magId "2332409793" @default.
• W2332409793 workType "article" @default.